ReviewBurns : journal of the International Society for Burn Injuries2012
Role of the PPAR-α agonist fenofibrate in severe pediatric burn.
Review in Burns : journal of the International Society for Burn Injuries, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Beyond diabetes: harnessing the power of metformin in burn care.Critical care (London, England) · 2025Review
- Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery.Journal of cellular and molecular medicine · 2025Review
- Exploring binding mode assessment of novel kaempferol, resveratrol, and quercetin derivatives with PPAR-α as potent drug candidates against cancer.Molecular diversity · 2023Article
- Impact of critical illness on cholesterol and fatty acids: insights into pathophysiology and therapeutic targets.Intensive care medicine experimental · 2023Review
- Objective perimetry identifies regional functional progression and recovery in mild Diabetic Macular Oedema.PloS one · 2023Article
- Burn-induced hypermetabolism and skeletal muscle dysfunction.American journal of physiology. Cell physiology · 2021Review
- Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences.Molecular autism · 2020Article
- Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.International journal of molecular sciences · 2019Review
- Myocardial Adipose Triglyceride Lipase Overexpression Protects against Burn-Induced Cardiac Lipid Accumulation and Injury.Oxidative medicine and cellular longevity · 2019Article
- Anticancer Properties of Fenofibrate: A Repurposing Use.Journal of Cancer · 2018Review
- Fibrates inhibit the apoptosis of Batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential.In vitro cellular & developmental biology. Animal · 2016Article
- Cardiovascular Dysfunction Following Burn Injury: What We Have Learned from Rat and Mouse Models.International journal of molecular sciences · 2016Review
- Stress hyperglycemia, insulin treatment, and innate immune cells.International journal of endocrinology · 2014Review
- Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.PloS one · 2014Article
- Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress.The Journal of surgical research · 2013Article
- Clinical review: Glucose control in severely burned patients - current best practice.Critical care (London, England) · 2013Review
- The controversy over H5N1 transmissibility research: an opportunity to define a practical response to a global threat.Human vaccines & immunotherapeutics · 2013Review
- Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.Diabetes · 2013Article
- Burns: an update on current pharmacotherapy.Expert opinion on pharmacotherapy · 2012Review
- Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity.Lipids in health and disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Fenofibrate is a peroxisome proliferator activated receptor alpha agonist that contains both pro and anti-inflammatory properties, and has been used in the treatment of dyslipidemia and diabetes for decades. Its receptors are expressed in the liver, skeletal muscle, cardiac, enteric, and renal cells, which allow it to provide systemic regulation of lipoprotein metabolism, fatty acid oxidation, and fatty acid transport. Hyperglycemia is a common complication found in the burn population because hepatic glucose production and catecholamine-mediated hepatic glycogenolysis are augmented. Insulin resistance occurs often in these patients and is associated with poor outcomes. In the pediatric burn population, fenofibrate has been found to ameliorate or decrease the number of hypoglycemic episodes when compared to management with insulin alone. Its mechanism of action is thought to involve an improvement in insulin signaling in skeletal muscle, as well as improvements in mitochondrial function, glucose oxidation, and insulin sensitivity. The long term use of fenofibrate in severely burned patients may improve hyperglycemia and insulin resistance, as well as improve wound healing, and reduce apoptosis, and oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.